FDA’s biosimilars director says agency seeks to ‘streamline’ developmentnews2025-10-28T18:41:12+00:00October 28th, 2025|Endpoints News|
Eli Lilly, Nvidia say they’ll build pharma’s most powerful supercomputernews2025-10-28T18:30:18+00:00October 28th, 2025|Endpoints News|
Genesis Molecular AI claims its model Pearl beats AlphaFold 3news2025-10-28T18:30:15+00:00October 28th, 2025|Endpoints News|
More than a third of Lilly’s new Zepbound prescriptions are coming from DTCnews2025-10-28T16:28:14+00:00October 28th, 2025|Endpoints News|
BioMarin looks to divest hemophilia gene therapy Roctaviannews2025-10-28T15:29:37+00:00October 28th, 2025|Endpoints News|
Regeneron discloses CRL; AbbVie stops work on Dragonfly assetnews2025-10-28T14:37:24+00:00October 28th, 2025|Endpoints News|
UK government delays drug rebate scheme deadline for drugmakers news2025-10-28T14:02:16+00:00October 28th, 2025|Endpoints News|
GHO Capital gets $2.9B for fourth healthcare PE fundnews2025-10-28T11:07:34+00:00October 28th, 2025|Endpoints News|
GSK to license Empirico’s COPD candidate for $85M upfrontnews2025-10-28T11:04:14+00:00October 28th, 2025|Endpoints News|
Startup launches with $80M and a plan to teach the immune system to make better Tregsnews2025-10-28T11:00:34+00:00October 28th, 2025|Endpoints News|
